Subcutaneous immunoglobulin and support program : What level of interest of patients ?;Immunoglobulines sous-cutanées et programme d'accompagnement : Quel est l'intérêt des patients ?

Revue Medicale Suisse

Volumn 11, Issue 469, 2015, Pages 831-835

  Bourdin, Aline ^a   Berger, Jérôme ^a   Bugnon, Olivier ^a   Früh, Aline ^b   Spertini, François ^c  

^a POLICLINIQUE MÉDICALE UNIVERSITAIRE   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; IMMUNOTHERAPY; LONG TERM CARE; PATIENT PREFERENCE; PATIENT SATISFACTION; QUALITY OF LIFE; COMPARATIVE STUDY; DRUG SELF ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

HUMANS; IMMUNOGLOBULINS; IMMUNOGLOBULINS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; PATIENT SATISFACTION; QUALITY OF LIFE; SELF ADMINISTRATION;

EID: 84927597928     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. APIIEG. Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency. Asia Pacific Immunoglobulins in Immunology Expert Group, 2009.
2. Buss G, Comte D, Spertini F, et al. Immunodéficience commune variable : ce qu'il faut savoir. Rev Med Suisse 2012;8:859-64.
3. Swissmedicinfo. www.swissmedicinfo.ch/
4. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142:1-11.
5. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008;28:779-802, viii.
6. Stiehm ER. Adverse effects of human immunoglobulin therapy. Transfus Med Rev 2013;27:171-8.
7. Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies : Systematic review and meta analysis. J Clin Immunol 2012;32:1180-92.
8. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency : Advancements into the 21st century. Ann Allergy Asthma Immunol 2008;101:114-21 ; quiz 22-3, 78.
9. Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 2000;20:94-100.
10. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies-a prospective, multi-national study. J Clin Immunol 2006;26:177-85.
11. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency : From subcutaneous to intravenous infusions and back again. J Clin Immunol 2012; 32:1153-64.
12. Perraudin C, Bourdin A, Berger J, et al. Economic evaluation of an interprofessional drug therapy management program : Switching patients with primary antibody deficiencies to home-based subcutaneous immunoglobulin. International Society for Pharmacoeconomics and Outcomes Research ; 8-12 November 2014 ; Amsterdam, 2014.
13. Krantz DS, Baum A, Wideman M. Assessment of preferences for self-treatment and information in health care. J Pers Soc Psychol 1980;39:977-90.
14. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies : Advantages of the subcutaneous route. Biodrugs 2007;21:105-16.
15. Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% IG SC preparation : A practical approach. Adv Ther 2011;28:521-33.
16. Torgerson TR, Bonagura VR, Shapiro RS. Clinical ambiguities-ongoing questions. J Clin Immunol 2013; 33(Suppl. 2):S99-103.
17. Bhole MV, Burton J, Chapel HM. Self-infusion programmes for immunoglobulin replacement at home : Feasibility, safety and efficacy. Immunol Allergy Clin North Am 2008;28:821-32, ix.
18. Henderson K. Training and support to enable home immunoglobulin therapy. Nurs Times 2003;99:28-31.
19. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006;6:434-42.
20. Chapel H, Gardulf A. Subcutaneous immunoglobulin replacement therapy : The European experience. Curr Opin Allergy Clin Immunol 2013;13:623-9.
21. Bourdin A, Berger J, Bugnon O. Immunoglobulin self-infusion : An interprofessional drug therapy management program. 42nd ESCP Symposium on Clinical Pharmacy : Implementation of Pharmacy Practice ; Prague, Czech Republic, 16-18 October 2013. Int J Clin Pharm 2013;35(6)CP-PC26.
22. Atkinson MJ, Kumar R, Cappelleri JC, et al. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. ValueHealth 2005;8 (Suppl. 1):S9-S24.
23. Daly PB, Evans JH, Kobayashi RH, et al. Homebased immunoglobulin infusion therapy : Quality of life and patient health perceptions. Ann Allergy 1991;67: 504-10.
24. Nicolay U, Haag S, Eichmann F, et al. Measuring treatment satisfaction in patients with primary immunodeficiency diseases receiving lifelong immunoglobulin replacement therapy. Qual Life Res 2005;14:1683-91.
25. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006;26:65-72.